<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00495508</url>
  </required_header>
  <id_info>
    <org_study_id>Mba/06/MIP</org_study_id>
    <nct_id>NCT00495508</nct_id>
  </id_info>
  <brief_title>Quinine vs. Artemether/Lumefantrine in Uncomplicated Malaria During Pregnancy</brief_title>
  <official_title>A Randomised, Open-label Non-inferiority Trial of Artemether-lumefantrine Versus Quinine for the Treatment of Uncomplicated Falciparum Malaria During Pregnancy, Mbarara, Uganda (2006-2007)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epicentre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medecins Sans Frontieres, Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shoklo Malaria Research Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Epicentre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A) for the treatment of uncomplicated malaria during second and third trimester pregnancy to&#xD;
      oral Quinine hydrochloride. The PCR-corrected adequate clinical and parasitological response&#xD;
      (ACPR) on day 42 is considered as the primary efficacy criterion. Newborns will be followed&#xD;
      for growth and development indicators.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Title:&#xD;
&#xD;
      Efficacy and Safety of Quinine vs Artemether/Lumefantrine in uncomplicated malaria during&#xD;
      pregnancy, Mbarara, Uganda (2006/2007).&#xD;
&#xD;
      Regulatory Status:&#xD;
&#xD;
      Investigational - Phase IV&#xD;
&#xD;
      Investigational Product and route:&#xD;
&#xD;
        -  Quinine hydrochloride, oral route.&#xD;
&#xD;
        -  Coartem® (Novartis Pharma AG, Basel, Switzerland), oral route.&#xD;
&#xD;
      Lead Investigator and Study Centre Primary objective - To establish that, in pregnant women&#xD;
      with uncomplicated Plasmodium falciparum malaria, the PCR-adjusted efficacy of&#xD;
      Artemether/Lumefantrine is not inferior to oral Quinine.&#xD;
&#xD;
      Secondary objectives&#xD;
&#xD;
        -  To define the pharmacokinetics of the combination artemether-lumefantrine (AL) in the&#xD;
           treatment of uncomplicated P. falciparum infections in the last two trimesters of&#xD;
           pregnancy.&#xD;
&#xD;
        -  To collect baseline data on maternal, obstetric and infant outcomes.&#xD;
&#xD;
        -  To estimate the incidence of malaria infection, both microscopic and sub-microscopic (by&#xD;
           PCR) during pregnancy.&#xD;
&#xD;
        -  women attending Mbarara National Referral Hospital (MNRH) ante-natal clinic (ANC).&#xD;
&#xD;
        -  Women with a positive blood smear during follow-up will be invited to participate in a&#xD;
           non-inferiority, open, randomised, non- inferiority trial comparing the efficacy and&#xD;
           tolerance of Coartem® (Artemether-Lumefantrine) for the treatment of uncomplicated&#xD;
           malaria during second and third trimester pregnancy to oral Quinine hydrochloride.&#xD;
           PCR-corrected adequate clinical and parasitological response (ACPR) on day 42 is&#xD;
           considered as the primary efficacy criterion.&#xD;
&#xD;
        -  Women with uncomplicated malaria from the efficacy study, will be followed to obtain an&#xD;
           efficacy endpoint at 42 days OR at delivery, whichever timepoint is the last.&#xD;
&#xD;
        -  Newborns will be followed monthly up to the age of 1 year.&#xD;
&#xD;
      Inclusion Criteria (Efficacy Study):&#xD;
&#xD;
        -  Pregnant woman&#xD;
&#xD;
        -  Malaria infection, detected by microscopy, with P. falciparum (mixed or mono-infection)&#xD;
&#xD;
        -  Age of gestation: 13 weeks and beyond&#xD;
&#xD;
        -  Efficacy study signed informed consent form&#xD;
&#xD;
      Exclusion Criteria (Efficacy Study):&#xD;
&#xD;
        -  P. falciparum parasitaemia above 250,000 parasites/μl&#xD;
&#xD;
        -  Severe anaemia&#xD;
&#xD;
        -  Signs or symptoms of severe/complicated malaria requiring parenteral treatment (WHO&#xD;
           2000)&#xD;
&#xD;
        -  Known allergy to artemisinin derivatives, lumefantrine or quinine;&#xD;
&#xD;
        -  Previous participation in the efficacy study&#xD;
&#xD;
        -  Inability to attend the efficacy study follow-up schedule.&#xD;
&#xD;
      Study drugs and Administration&#xD;
&#xD;
        -  Group 1 (Active Control): Quinine hydrochloride (10 mg/Kg/8h for 7 days) administered&#xD;
           orally.&#xD;
&#xD;
        -  Group 2 (Test): Coartem®, fixed Artemether-Lumefantrine (20/120 mg) GMP manufactured by&#xD;
           Novartis Pharma AG (Basel, Switzerland), 4 tablets twice a day for 3 days with 200 ml of&#xD;
           milk tea at each dose .&#xD;
&#xD;
      Endpoints&#xD;
&#xD;
      - Primary efficacy endpoint: PCR-corrected adequate clinical and parasitological response&#xD;
      (ACPR) on Day 42.&#xD;
&#xD;
        -  Secondary efficacy endpoints:&#xD;
&#xD;
        -  PCR-corrected(ACPR)at delivery&#xD;
&#xD;
        -  Pharmacokinetic parameters&#xD;
&#xD;
        -  Symptom clearance Time&#xD;
&#xD;
        -  Proportion of patients who have fever cleared at Day 1, 2 and 3&#xD;
&#xD;
        -  Safety endpoints:&#xD;
&#xD;
        -  Incidence of any adverse events&#xD;
&#xD;
        -  Pregnancy outcome&#xD;
&#xD;
        -  Infant development during the first year of life&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2006</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PCR-corrected adequate clinical and parasitological response (ACPR) on Day 42 or at delivery.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy outcome</measure>
    <time_frame>3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant development during the first year of life</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histopathological findings in the placenta</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Quinine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arthemeter lumefantrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quinine</intervention_name>
    <arm_group_label>Quinine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>artemether / lumefantrine</intervention_name>
    <arm_group_label>Arthemeter lumefantrine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Cohort Study:&#xD;
&#xD;
          -  Weeks of pregnancy between 13 and 22 weeks&#xD;
&#xD;
          -  Resident in Mbarara Municipality (radius of 15km from MNRH)&#xD;
&#xD;
          -  Cohort study signed informed consent form&#xD;
&#xD;
        Efficacy Study:&#xD;
&#xD;
          -  Pregnant woman&#xD;
&#xD;
          -  Malaria infection, detected by microscopy, with P. falciparum (mixed or&#xD;
             mono-infection)&#xD;
&#xD;
          -  Age of gestation: 13 weeks and beyond&#xD;
&#xD;
          -  Efficacy study signed informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Efficacy Study:&#xD;
&#xD;
          -  P. falciparum parasitaemia above 250,000 parasites/μl&#xD;
&#xD;
          -  Severe anaemia&#xD;
&#xD;
          -  Signs or symptoms of severe/complicated malaria requiring parenteral treatment (WHO&#xD;
             2000)&#xD;
&#xD;
          -  Known allergy to artemisinin derivatives, lumefantrine or quinine;&#xD;
&#xD;
          -  Previous participation in the efficacy study&#xD;
&#xD;
          -  Inability to attend the efficacy study follow-up schedule.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrice Piola, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Epicentre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe J Guerin, MD, MPH, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Epicentre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth Ashley, MB BS</last_name>
    <role>Study Chair</role>
    <affiliation>Epicentre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rose McGready, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Shoklo Malaria Research Unit (SMRU)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>François Nosten, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>SMRU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Epicentre</name>
      <address>
        <city>Mbarara</city>
        <state>Mbarara District</state>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 2, 2007</study_first_submitted>
  <study_first_submitted_qc>July 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2007</study_first_posted>
  <last_update_submitted>May 31, 2022</last_update_submitted>
  <last_update_submitted_qc>May 31, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quinine</keyword>
  <keyword>Artemether</keyword>
  <keyword>Lumefantrine</keyword>
  <keyword>malaria</keyword>
  <keyword>Uganda</keyword>
  <keyword>Artemisinin- based combination therapy</keyword>
  <keyword>pregnancy</keyword>
  <keyword>Malaria In Pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Quinine</mesh_term>
    <mesh_term>Artemether, Lumefantrine Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

